PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will hold a conference call on March 30, 2011 to discuss the financial results for the fourth quarter ended December 31, 2010. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
The conference call is scheduled to begin at 11:00 a.m. ET (Eastern Time). The results will be released before the opening of the market that same day.
To access the conference call, U.S.-based listeners should dial (888) 563-6275 and international listeners should dial (706) 634-7417. All listeners should provide the following passcode: 54576672.
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website, www.dermasciences.com. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast.
Following the end of the conference call, a replay will be available through April 6, 2011, and can be accessed by dialing (800) 642-1687 within the U.S. or (706) 645-9291 outside of the U.S. All listeners should provide the following passcode: 54576672. The webcast will also be available for 30 days.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.
For more information please visit www.dermasciences.com.